Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

Published:2017-08 Issue:8 Volume:2 Page:565-575
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Meyer Tim,Fox Richard,Ma Yuk Ting,Ross Paul J,James Martin W,Sturgess Richard,Stubbs Clive,Stocken Deborah D,Wall Lucy,Watkinson Anthony,Hacking Nigel,Evans T R Jeffry,Collins Peter,Hubner Richard A,Cunningham David,Primrose John Neil,Johnson Philip J,Palmer Daniel H

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference29 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma;J Hepatol,2012

3. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial;Llovet;Lancet,2002

4. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival;Llovet;Hepatology,2003

5. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma;Lo;Hepatology,2002

Cited by 396 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Therapies for Hepatocellular Carcinoma in India;Journal of Clinical and Experimental Hepatology;2024-11

2. Current research status of transarterial therapies for hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-09-15

3. Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis;Journal of Hepatocellular Carcinoma;2024-08

4. TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study;Frontiers in Immunology;2024-07-26

5. Maximizing therapeutic outcomes in hepatocellular carcinoma: Insights into combinatorial strategies;World Journal of Gastrointestinal Oncology;2024-07-15